A pseudosubstrate peptide inhibitor of protein kinase c; inactive control for PKC.
[Glu27]-PKC (19-36) is a synthetic peptide fragment derived from the regulatory domain of protein kinase C (PKC), specifically encompassing residues 19 to 36 with a glutamic acid substitution at position 27. As a modified peptide, it serves as a valuable molecular tool for probing the structure-function relationships within the PKC family of serine/threonine kinases. The deliberate sequence alteration enhances its utility in dissecting the role of specific amino acid residues in PKC-mediated signaling events. Its biochemical relevance lies in its capacity to mimic or competitively inhibit native PKC interactions, enabling researchers to investigate the mechanistic basis of PKC activation, substrate recognition, and downstream signaling cascades in cellular and biochemical contexts.
Signal transduction research: [Glu27]-PKC (19-36) is frequently employed to elucidate the molecular mechanisms underlying PKC-mediated signal transduction pathways. By acting as a substrate analog or competitive inhibitor, the peptide allows researchers to modulate PKC activity in vitro and in cell-based assays. This targeted approach facilitates the study of phosphorylation events, protein-protein interactions, and the broader regulatory networks that govern cellular responses to external stimuli. Its use contributes to a deeper understanding of how PKC isoforms orchestrate diverse physiological processes such as proliferation, differentiation, and apoptosis through precise signal relay mechanisms.
Protein-protein interaction studies: The peptide's defined sequence and site-specific modification make it an effective probe for mapping interaction domains within PKC and its binding partners. By introducing [Glu27]-PKC (19-36) into biochemical assays, researchers can competitively disrupt or mimic endogenous interactions, thereby identifying critical contact points and conformational changes required for PKC function. This application is particularly valuable in structural biology and proteomics, where delineating interaction motifs informs the development of selective modulators and enhances knowledge of kinase regulatory mechanisms.
Peptide inhibitor development: Due to its ability to interfere with PKC regulatory domains, [Glu27]-PKC (19-36) is utilized as a lead structure in the design and optimization of peptide-based inhibitors. Its sequence serves as a template for structure-activity relationship studies, guiding the rational modification of peptide analogs to improve specificity and potency against targeted PKC isoforms. Such research supports the broader effort to develop molecular tools for dissecting kinase signaling and offers foundational insights for future therapeutic exploration, strictly within research settings.
Enzyme kinetics and substrate specificity assays: The synthetic peptide is widely used to characterize the kinetic properties and substrate preferences of PKC isoforms. By serving as a defined substrate or competitive modulator in enzymatic assays, it enables quantitative assessment of phosphorylation rates, catalytic efficiency, and inhibitor sensitivity. These studies are instrumental in profiling the functional diversity of PKC family members and in validating assay platforms for biochemical screening.
Cell signaling pathway mapping: In cell-based experiments, [Glu27]-PKC (19-36) is introduced to modulate PKC activity and monitor downstream effects on signaling networks. Researchers leverage its selective interaction with PKC regulatory domains to dissect pathway cross-talk, feedback regulation, and context-dependent signaling outcomes. The peptide's application in these studies advances the understanding of how PKC integrates external and internal cues to shape complex cellular behaviors, providing a robust tool for mapping dynamic signaling architectures in both basic and applied research contexts.
1. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
3. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes
4. The spatiotemporal control of signalling and trafficking of the GLP-1R
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More